Understanding BET inhibition as a novel pathway for cardiovascular risk modulation.

ESC Premium Access

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation.

Session: A novel approach for high CV risk patients with diabetes: the potential of epigenetics

Topic: Primary cardiovascular prevention: interventions and outcomes

Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by an unrestricted educational grant from Resverlogix

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Doctor Jorge Plutzky

Brigham and Women's Hospital, Boston (United States of America)

5 presentations

0 follower

4 more presentations in this session

Introduction - A novel approach for high CV risk patients with diabetes: the potential of epigenetics.

Speaker: Professor S. Del Prato (Pisa, IT)

Access

The high risk diabetes patient with cardiovascular disease: what else can we target to reduce cardiovascular risk?

Speaker: Professor K. Ray (London, GB)

Access

BET inhibition in cardiovascular disease: a new dawn?

Speaker: Professor J. Kastelein (Amsterdam, NL)

Access

Discussion & summary - A novel approach for high CV risk patients with diabetes: the potential of epigenetics.

Speaker: Professor K. Ray (London, GB) Professor S. Del Prato (Pisa, IT)

Access

Access the full session

A novel approach for high CV risk patients with diabetes: the potential of epigenetics

Speakers: Doctor J. Plutzky, Professor S. Del Prato, Professor K. Ray, Professor J. Kastelein, Professor K. Ray...

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources